SCHEDULE: Sarepta Fully Divests Arrowhead Pharmaceuticals Stake

Sarepta Therapeutics has fully divested its stake in Arrowhead Pharmaceuticals through a secondary sale and a share redemption tied to a milestone payment.

Summary

• Sarepta Therapeutics Investments sold 9,265,312 shares of Arrowhead Pharmaceuticals Common Stock at $18.79 per share in a privately negotiated block trade.
• Concurrently, Arrowhead Pharmaceuticals redeemed 2,660,989 shares from Sarepta Investments at $18.79 per share.
• The redemption satisfied Sarepta's obligation to pay Arrowhead $49,999,983.31 for the DM1 First Development Milestone Payment under a collaboration agreement.
• Following these transactions, Sarepta Therapeutics and its investment arm no longer beneficially own any shares of Arrowhead Pharmaceuticals, ceasing to be a greater than 5% beneficial owner as of August 13, 2025.

Sentiment

Score: 6

Explanation: Neutral to slightly positive for Arrowhead as it receives a milestone payment and cleans up its cap table by redeeming shares. Slightly negative for Arrowhead due to a large institutional investor fully exiting. Neutral for Sarepta as it monetizes an asset.

Positives

• For Arrowhead: Received $49,999,983.31 in cash (or equivalent in share redemption) from Sarepta for a development milestone, indicating progress in their collaboration.
• For Arrowhead: The redemption of 2,660,989 shares reduces the outstanding share count, which can be accretive to earnings per share.
• For Sarepta: Monetized its investment in Arrowhead, potentially freeing up capital for other strategic initiatives.

Negatives

• For Arrowhead: A significant institutional investor (Sarepta) has fully exited its position, which could be perceived negatively by the market and potentially lead to short-term selling pressure.
• For Sarepta: No longer holds an equity stake in Arrowhead, potentially missing out on future upside if Arrowhead's stock performs well.

Future Outlook

NA

Industry Context

This transaction reflects a strategic adjustment in a prior collaboration between two biotechnology companies. Such divestments can occur as partnerships evolve or as one party seeks to reallocate capital. The specific milestone payment suggests progress in a drug development program (DM1), indicating the collaboration achieved a defined objective.

Related Party Transactions

• The redemption of shares from Sarepta Therapeutics Investments by Arrowhead Pharmaceuticals, tied to a milestone payment from Sarepta Therapeutics, constitutes a related party transaction given their prior collaboration agreement.

Stakeholder Impact

• Shareholders (Arrowhead): A large institutional holder (Sarepta) has fully exited, which could lead to short-term selling pressure or concerns about institutional confidence. However, the redemption of shares reduces the outstanding share count, which can be positive for earnings per share.
• Shareholders (Sarepta): Sarepta has monetized an asset, potentially providing capital for other investments or operations.

Key Dates

Recommendation

The filing details a significant divestment by Sarepta Therapeutics from Arrowhead Pharmaceuticals, including a large block trade and a share redemption tied to a milestone payment. While the milestone payment is a positive for Arrowhead, indicating progress in a collaboration, the full exit by a major institutional investor could create short-term uncertainty or selling pressure. For Sarepta, it represents a monetization of an asset. Given the mixed signals and the nature of the transaction as a pre-planned event rather than a new operational development, a 'hold' recommendation is appropriate until further operational or financial updates from Arrowhead provide clearer direction.

Keywords

Arrowhead Pharmaceuticals, Sarepta Therapeutics, Share Sale, Stock Redemption, Beneficial Ownership, SEC Filing, Schedule 13D, Biotechnology, Pharmaceuticals, Collaboration Agreement, Milestone Payment